Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Soiken Holdings Inc. (2385.T)
Toyonaka, JP
Founded in 1994 and headquartered in Toyonaka, Japan, Soiken Holdings Inc. primarily focuses on the advancement of biomarkers. The company’s operations span a diverse range of health and wellness sectors. It is actively involved in the creation and commercialization of cosmetics and nutritional supplements, alongside the licensing and continued development of biomarker technologies. Soiken also conducts market research and post-market surveillance specifically for dietary supplements. A key area of its work includes the research, development, and sale of functional materials like lactoferrin, as well as pharmaceuticals derived from ascochlorin. Furthermore, Soiken applies its biomarker expertise to perform clinical evaluations for food products. The company extends its services to provide vital support for physician-initiated pharmaceutical clinical research, comprehensive health screenings, and personalized health guidance. It also partners with health insurance societies to offer contracted health guidance, facilitate specialized health check-ups for dependents of the insured, and implement programs designed for diabetes prevention.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.28% | +1.18% | +4.05% | -2.28% | +14.73% | +8.44% | +63.69% | -6.55% | -47.76% | -28.61% | -91.97% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-6.0% Q1'26: -17.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+68.2% ★ Q1'26: +14.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+6.3% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-4.6% Q1'26: +11.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-28.3% Q1'26: +60.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
|---|---|---|---|---|---|---|---|---|
| Revenue |
5.46B
est: 5.50B (-0.8%)
|
7.57B
est: 7.60B (-0.4%)
|
9.31B
est: 9.00B (+3.5%)
|
8.94B
est: 9.69B (-7.7%)
|
9.35B
est: 8.87B (+5.4%)
|
8.08B
est: 8.19B (-1.3%)
|
5.16B
est: 8.58B (-39.9%)
|
4.85B
est: 8.97B (-45.9%)
|
| EBITDA |
363.95M
est: 193.65M (+87.9%)
|
901.32M
est: 267.54M (+236.9%)
|
1.08B
est: 316.82M (+241.8%)
|
948.13M
est: 341.11M (+178.0%)
|
1.23B
est: 312.25M (+294.8%)
|
750.07M
est: 288.31M (+160.2%)
|
-583.21M
est: 302.04M (-293.1%)
|
-201.93M
est: 315.77M (-163.9%)
|
| EBIT |
332.36M
est: 173.71M (+91.3%)
|
866.83M
est: 239.99M (+261.2%)
|
1.05B
est: 284.19M (+268.7%)
|
916.79M
est: 305.98M (+199.6%)
|
1.21B
est: 280.09M (+331.6%)
|
725.72M
est: 258.62M (+180.6%)
|
-610.01M
est: 270.93M (-325.2%)
|
-220.39M
est: 283.25M (-177.8%)
|
| Net Income |
197.98M
est: 287.74M (-31.2%)
|
553.47M
est: 520.55M (+6.3%)
|
731.69M
est: 601.64M (+21.6%)
|
562.06M
est: 879.99M (-36.1%)
|
809.71M
est: 669.99M (+20.9%)
|
451.85M
est: 559.99M (-19.3%)
|
-662.20M
est: 609.98M (-208.6%)
|
-210.70M
est: 660.00M (-131.9%)
|
| SGA |
2.64B
est: 2.34B (+13.0%)
|
2.99B
est: 3.23B (-7.3%)
|
3.10B
est: 3.82B (-18.9%)
|
3.10B
est: 4.12B (-24.7%)
|
3.00B
est: 3.77B (-20.5%)
|
2.91B
est: 3.48B (-16.3%)
|
3.02B
est: 3.65B (-17.2%)
|
2.48B
est: 3.81B (-35.0%)
|
| EPS |
7.57
est: 11.00 (-31.2%)
|
21.16
est: 19.90 (+6.3%)
|
27.97
est: 23.00 (+21.6%)
|
21.49
est: 33.64 (-36.1%)
|
30.95
est: 25.61 (+20.8%)
|
17.27
est: 21.41 (-19.3%)
|
-25.32
est: 23.32 (-208.6%)
|
-8.05
est: 25.23 (-131.9%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kentaro Ishigami | President & Chairman | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2385.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
